Explore results from AstraZeneca's EMERALD-1 Phase 3 trial on Imfinzi for unresectable hepatocellular carcinoma. Statistically significant improvement in progression-free survival with Imfinzi plus TACE and bevacizumab. Presented at ASCO Gastrointestinal Cancers Symposium.
Explore Novo Holdings' 2024 plans for acquisitions and investments in Asia, led by CEO Kasim Kutay. Discover strategic initiatives, global studies on NVO drugs, and insights into challenges and opportunities.
Novocure's TTFields therapy gains FDA acceptance for non-small cell lung cancer treatment after platinum-based therapy. PMA filing under FDA review. Decision expected in 2H 2024.
Biden Administration's rule for health information exchange and prior authorization processes in government-backed insurance plans. Streamlined procedures, reduced wait times, and estimated $15 billion savings by 2026.